Просмотр по автору "Hanker, L. Ch."
Отображаемые элементы 1-1 из 1
-
Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial
Mirza, M.; Ghamande, Sh.; Hanker, L. Ch.; Black, D.; Raascou-Jensen, N.; Gilbert, L.; Oaknin, A.; Secord, A. A.; Savarese, A.; Holloway, R. W.; Kristeleit, R.; Buscema, J.; Boere, I. A.; Sharma, S.; Gennigens, Ch.; Ghatage, P.; Yablons, K.; Stevens, S.; Trukhan, H.; Powell, M. (2024)Background: In Part 1 of the phase 3 RUBY trial (NCT03981796) in pA/rEC, patients (pts) receiving dostarlimab (dostar)/carboplatin-paclitaxel (CP) exhibited significant benets in PFS and overall survival versus CP alone. ...
